ICPB SURVMARK-2 aims to establish the most up-to-date international cancer survival benchmarks for cancers of the lung, oesophagus, stomach, ovary, colon, rectum, liver, and pancreas across seven comparable high-income countries, as well as to provide a greater understanding of the impact of stage at diagnosis and stage-specific survival. This work will be carried out in three Elements (A, B, and C).

For each jurisdiction and for each cancer, ICBP SURVMARK-2 will:

A. Provide up-to-date measures of cancer survival, incidence, and mortality.
B. Provide an overview of jurisdiction adherence to international coding frameworks, including staging classifications, to enable robust comparisons and to recommend how these could be harmonized.
C. Quantify the impact of local registration practices on short-term cancer survival, to improve the sensitivity of international comparisons.

Source: ICBP at Cancer Research UK

The SurvMark2 project has been approved by the IARC Ethics Committee (IEC).